The Latest Breaking News from WAVE Life Sciences

Wave Life Sciences Ltd. (NASDAQ:WVE) stock rose Tuesday on continued optimism after the company announced data from the lowest therapeutic cohort of the ongoing INLIGHT trial of WVE-007 for weight loss.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

The ‘Die Hard’ actor’s family announced he had been diagnosed with frontotemporal dementia earlier this year

U.S. stocks traded slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

WAVE Life Sciences (NASDAQ:WVE) brought in sales totaling $1.75 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 8.71%, resulting in a loss of $37.81 million.

  WAVE Life Sciences (NASDAQ:WVE) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

WAVE Life Sciences (NASDAQ:WVE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that WAVE Life Sciences will report an earnings per share (EPS) of $-0.55.

 

Wave Life Sciences Ltd's (NASDAQ: WVE)